Compare Ascendis Pharma A/S (ASND) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs PulteGroup, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while PulteGroup, Inc. trades at $124.58 (market cap $23.76B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.83% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PHM | |
|---|---|---|
Market Cap | $17.74B | $23.76B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $142.56 |
52-Week Low | $163.32 | $108.00 |
Enterprise Value | $18.11B | $23.72B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PulteGroup (PHM) trades at $124.75, up 0.83% on the day, with a bearish technical signal despite recent price strength. The stock shows mixed earnings performance with Q3 2025 beating estimates but subsequent quarters missing, while maintaining solid profitability with a 12.14% net margin. Recent news highlights new community developments and sector attention, though technical indicators suggest caution with RSI at neutral levels and key resistance at $125.
The outlook for PHM is balanced; analyst consensus targets $150.60 (21% upside) with 45% buy ratings, but near-term risks include margin pressure and housing market volatility. Earnings growth remains the key catalyst for sustained upside, while macroeconomic factors pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
